Trial · NCT07246447
Ketodex Versus Opioid Based Anesthesia in Obese Patients Undergoing Laparoscopic Sleeve Gastrectomy.
NCT07246447, Not applicable, Active not recruiting, Cairo University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Ketodex Versus Opioid Based Anesthesia in Obese Patients Undergoing Laparoscopic Sleeve Gastrectomy. Trials, record NCT07246447. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07246447
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Ketodex Versus Opioid Based Anesthesia in Obese Patients Undergoing Laparoscopic Sleeve Gastrectomy.
- NCT number
- NCT07246447
- Status
- Active not recruiting
- Phases
- Not applicable
- Enrollment
- 8 participants, estimated
- Lead sponsor
- Cairo University
- Conditions
- Morbid Obesity
- Interventions
- ketamine and dexmeditomidine combination, Fentanyl (IV)
- First posted
- 2025-11-24
- Last updated
- 2026-04-08
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Total nalbuphine consumption (mg) during the first 24 hours postoperatively. | during the first 24 hours postoperatively | Total nalbuphine consumption (mg) during the first 24 hours postoperatively. |
| Secondary | Total intraoperative titrated fentanyl dose for each patient. | intraoperative time | |
| Secondary | Time to extubation, defined as the interval between discontinuation of anesthesia and tracheal extubation | the interval between discontinuation of anesthesia and tracheal extubation | |
| Secondary | • Time to first postoperative rescue analgesia | during 1st 24 hrs postoperatively. | |
| Secondary | Postoperative sedation scores. | 1st 24 hours postoperatively | Sedation assessment: All patients will be monitored postoperatively in the post-anesthesia care unit (PACU) and ward. Sedation will be assessed using the Modified Observer's Assessment of Alertness/Sedation Scale (MOASS) . Scores will be recorded at 0, 10, 30, and 60 minutes from PACU admission. |
| Secondary | Postoperative pain scores assessed using the Numerical Rating Scale (NRS). | 1st 24 hours post operatively | Postoperative pain: Pain will be assessed using the Numerical Rating Scale (NRS, 0 = no pain, 10 = worst pain). Patients will be instructed preoperatively regarding the scale. NRS scores will be recorded at 0, 30, and 60 minutes, and at 2, 6, 12, and 24 hours after surgery. |
| Secondary | Postoperative nausea and vomiting (PONV) scores | 1st 24 hours postoperatively | by using Simplified PONV Impact Scale (SPONVIS) This simplified version, often used for audit and post-discharge review, uses just two main components: Nausea Impact and Vomiting Impact. 1. Nausea Impact," Based on the patient's assessment of how much the nausea affected their recovery (e.g., ability to eat, walk, or be discharged).","0 to 5 Points (e.g., 0 = No Impact, 5 = Severe Impact/Required hospital stay)" 2. Vomiting/Retching, Total number of vomiting or retching episodes.,"0 to 5 Points (e.g., 0 = None, 5 = ≥3 episodes)" Total SPONVIS Score Sum of Nausea Impact + Vomiting/Retching Points, Score: 0 to 10 Cut-off for CIPONV Total Score ≥5 |
| Secondary | Patient satisfaction scores . | during 1st 24 hours postoperatively. | (0 = not satisfied, 10 = highly satisfied). |
| Secondary | Length of hospital stay | 1-2 weeks | From date of randomization until the date of first documented progression |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07246447
GET https://conductscience.org/api/trials/v1/NCT07246447/registered